COVID-19: Mylan to launch remdesivir in India at Rs 4,800 per 100 mg vial
https://ift.tt/2NszK0i
Pharmaceutical major Mylan NV announced that it has received approval from Indian drugs regulator DCGI to manufacture and market its remdesivir for restricted emergency use in the country for the treatment of COVID-19. The drug will be priced at Rs 4,800 per 100 mg vial and would be available to the patients in this month.
Pharmaceutical major Mylan NV announced that it has received approval from Indian drugs regulator DCGI to manufacture and market its remdesivir for restricted emergency use in the country for the treatment of COVID-19. The drug will be priced at Rs 4,800 per 100 mg vial and would be available to the patients in this month.
No comments